A Vanderbilt study found that aspirin is as effective as low molecular weight heparin at preventing hospital-acquired deep venous thromboembolism, or blood clots in the veins, for orthopaedic trauma patients.
According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.
A certain genetic variant, in combination with the use of anti-inflammatory drugs like aspirin and ibuprofen during early pregnancy, may protect women from miscarriage.
New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
The Vanderbilt-based Mid-South Clinical Data Research Network (CDRN) is among seven CDRNs that will collaboratively mount a three-year, $14 million randomized clinical trial to determine the best daily dose of aspirin for preventing heart attacks and strokes among people living with heart disease.
Drugs such as aspirin and indomethacin may increase sensitivity to airborne allergens by suppressing production of the signaling molecule PGI2, which in turn may offer a new treatment for allergies.